Stonepine Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Stonepine Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$291K	Buy	+104,550	New	+$292K	0.16%	69

Other funds holding CLRB

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Empery Asset Management New York $86.5M AUM

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Stonepine Capital Management's CLRB Position: Q2 2026 in Review

Stonepine Capital Management opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 104,550 shares worth $291K. The stake represents 0.16% of the portfolio and ranks #69 among its holdings.

29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

Stonepine Capital Management held 104,550 shares of Cellectar Biosciences worth $291K as of Q2 2026.
Cellectar Biosciences was a new Stonepine Capital Management position in Q2 2026.
Cellectar Biosciences made up 0.16% of Stonepine Capital Management's portfolio in Q2 2026, its #69 holding.
29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.